$0.43
−3.15%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$0.44
From 52W high−66.32%
Volume609351.00
Market cap$56.08M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 29, 2026
Open
$0.44
From 52W high
−66.32%
Volume
609351.00
Market cap
$56.08M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
25.7
MomentumView details →
1D Return
−3.15%
YTD Return
−49.44%
SummaryUpdated Jun 1, 2026
Oncolytics Biotech Inc. (NASDAQ:ONCY) is a Canadian development-stage biopharmaceutical company founded in 1998 and headquartered in Calgary, Alberta. The company went public in 2001 and has spent over two decades developing its lead therapeutic candidate, pelareorep, an oncolytic virus-based immunotherapy for cancer treatment. As a clinical-stage biotechnology company, Oncolytics has no commercial products and generates no revenue, instead focusing entirely on advancing pelareorep through various clinical trials targeting multiple cancer types including breast, pancreatic, and anal cancers.
Similar companies
Latest newsMore news →
ONCOLYTICS BIOTECH INC reported GOBLET study data showing that all responding anal cancer patients survived for longer than one year.3d agoONCOLYTICS BIOTECH INC announced that it is presenting a trial-in-progress abstract and e-poster on the REO 033 study at the ESMO Congress 2026.10d agoOncolytics Biotech said it expects to receive the final payment under its grant from the Pancreatic Cancer Action Network, Inc. later in the fourth quarter of 2026.16d ago